Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Azilsartan,Chlorthalidone
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Gets FDA Tentative Approval for Hypertension Tablets
Details : Edarbyclor-Generic is an angiotensin II receptor blocker (ARB) and a thiazide like diuretic combination product indicated for the treatment of hypertension.
Brand Name : Edarbyclor-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 14, 2024
Lead Product(s) : Azilsartan,Chlorthalidone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Atenolol,Chlorthalidone
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Unichem Labs Receives ANDA Approval for Atenolol and Chlorthalidone Tablets
Details : Atenolol and Chlorthalidone Tablets are indicated for the treatment of hypertension, to lower blood pressure. It is generic version of Tenoretic (atenolol and chlorthalidone) tablets.
Brand Name : Atenolol/Chlorthalidone-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 28, 2020
Lead Product(s) : Atenolol,Chlorthalidone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?